StockData

Akebia Therapeutics vs Rockwell Medical

AKBA and RMTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AKBA and RMTI compare

Akebia Therapeutics is the larger company, worth 4.2 times as much as Rockwell Medical ($111M against $26.6M).

Akebia Therapeutics grew revenue faster over the last twelve months (7.5% versus −21.1% for Rockwell Medical).

Rockwell Medical keeps more of each dollar of sales as profit, with a net margin of −7.3% compared with −13.5% at Akebia Therapeutics.

Rockwell Medical scores higher on the StockData Score (11 against 6 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAKBARMTI
Size and price
Market cap$111M$26.6M
Share price$0.400$6.61
Change, 1 year−76.0%−28.1%
Change, 5 years−85.0%−86.3%
Beta (5Y)1.200.01
Employees194157
StockData Score
Total score611 (better)
Valuation score03 (better)
Growth score2 (better)1
Performance score23 (better)
Health score24 (better)
Dividend score00
Valuation
P/S0.5×0.4× (better)
P/B4.4×0.8× (better)
P/FCF2.8× (better)17.3×
FCF yield36.3% (better)5.8%
Fair value–$32.27
Margin of safety–79.5%
Growth
Revenue growth (TTM)7.5% (better)−21.1%
Revenue growth, 5Y average−4.3%2.2% (better)
Profitability
Gross margin79.6% (better)17.7%
Operating margin−6.9%−6.5% (better)
Net margin−13.5%−7.3% (better)
FCF margin18.4% (better)2.2%
Return on equity−109%−15.5% (better)
Return on invested capital–−17.9%
Financial health
Debt / equity1.980.26 (better)
Interest coverage–−4.0×
Current ratio1.433.25 (better)
Altman Z-score−5.89 (better)−7.81
Piotroski F-score7 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.7%0.05%
Held by insiders2.9%100%
Insider net buying, 12 months−$876K−$11.6K (better)
Short interest, % of float10.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.